Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient

Ann Oncol. 2018 Jan 1;29(1):286-287. doi: 10.1093/annonc/mdx548.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Humans
  • Liver Transplantation*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Male
  • Middle Aged
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab